Mrs Laura Alexander
- Affiliate -Clinical Trials Unit (School of Cancer Sciences)
email:
Laura.Alexander@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
Publications
2023
Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167)
2021
Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)
Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)
Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)
2020
Tsim, S., Cowell, G. W., Kidd, A., Woodward, R., Alexander, L., Kelly, C. , Foster, J. E. and Blyth, K. G. (2020) A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 150, pp. 12-20. (doi: 10.1016/j.lungcan.2020.09.025) (PMID:33039775)
Ferguson, J. et al. (2020) Staging by Thoracoscopy in Potentially Radically Treatable Non-Small Cell Lung Cancer Associated with Minimal Pleural Effusion (STRATIFY) study: a prospective multicentre study. Lung Cancer, 139(1), S92. (doi: 10.1016/S0169-5002(20)30245-2)
2019
Mileshkin, L. et al. (2019) Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, 154(1), pp. 29-37. (doi: 10.1016/j.ygyno.2019.05.007) (PMID:31130288)
Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C. , Holme, J., Evison, M. and Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017) (PMID:31200818)
2018
Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)
2017
Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)
Tsim, S., Stobo, D. B., Alexander, L., Kelly, C. and Blyth, K. G. (2017) The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 103, pp. 38-43. (doi: 10.1016/j.lungcan.2016.11.010) (PMID:28024694) (PMCID:PMC5226066)
2016
Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)
2011
Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi: 10.1186/1745-6215-12-S1-A30)
Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)
Articles
Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167)
Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)
Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)
Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)
Tsim, S., Cowell, G. W., Kidd, A., Woodward, R., Alexander, L., Kelly, C. , Foster, J. E. and Blyth, K. G. (2020) A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 150, pp. 12-20. (doi: 10.1016/j.lungcan.2020.09.025) (PMID:33039775)
Ferguson, J. et al. (2020) Staging by Thoracoscopy in Potentially Radically Treatable Non-Small Cell Lung Cancer Associated with Minimal Pleural Effusion (STRATIFY) study: a prospective multicentre study. Lung Cancer, 139(1), S92. (doi: 10.1016/S0169-5002(20)30245-2)
Mileshkin, L. et al. (2019) Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, 154(1), pp. 29-37. (doi: 10.1016/j.ygyno.2019.05.007) (PMID:31130288)
Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C. , Holme, J., Evison, M. and Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017) (PMID:31200818)
Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)
Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828) (PMID:28402747)
Tsim, S., Stobo, D. B., Alexander, L., Kelly, C. and Blyth, K. G. (2017) The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 103, pp. 38-43. (doi: 10.1016/j.lungcan.2016.11.010) (PMID:28024694) (PMCID:PMC5226066)
Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)
Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi: 10.1186/1745-6215-12-S1-A30)
Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)